Rheumatoid Arthritis & Interstitial Lung Disease Medication

Trial Objective

Rheumatoid Arthritis & Interstitial Lung Disease MedicationThe purpose of this study is to find out if people with rheumatoid arthritis and interstitial lung disease (ILD) can benefit from taking Pirfenidone.

Our researchers also want to determine if the medication can be taken safely without many side effects. Pirfenidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). This study will compare the results of taking Pirfenidone to those of a placebo, a medication that looks like Pirfenidone but does not contain the drug. Participants may receive Pirfenidone or a placebo.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have been diagnosed with rheumatoid arthritis and interstitial lung disease (RA-ILD) for at least six months.

Age: 18-85    Gender: Any Gender

Estimated Time Commitment

10 visits & 1 phone call (22 hours over 56 weeks)

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Kris Eliopoulos

Kris Eliopoulos

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Genentech, Inc.

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.